The market for Laboratory proficiency testing is expected to witness
significant growth during the forecast period. PT forms an essential
precondition for operational excellence and accreditation in several
industries. This is one of the major factors driving the growth of the laboratory
proficiency testing market globally. Also, the increasing number of laboratory
accreditations, stringent safety and quality regulations for food and
pharmaceutical products and the increasing focus on water testing are the other
major factors supporting market growth. However, the requirement of high
capital investments for accurate and sensitive testing is expected to restrain
the growth of this market during the forecast period.
The global Laboratory proficiency testing market is projected to reach USD 1.4 billion by 2026 from
USD 1.0 billion in 2021, at a CAGR of 6.4%.
With proficiency testing being a mandatory procedure to be undertaken by laboratories functioning in different industries which are under regulation by organizations such as the CLIA, APLAC, and CLSI,
The prominent players in
the laboratory proficiency testing market are LGC Limited (UK), American
Proficiency Institute (US), College of American Pathologists (US), Bio-Rad
Laboratories (US), Randox Laboratories (UK), Merck (Germany), Fapas (Fera
Science Ltd.) (UK), Waters Corporation (US), Weqas (UK), AOAC INTERNATIONAL
(US), BIPEA (France), NSI Lab Solutions (US), Absolute Solutions (US), Trilogy
Analytical Laboratories (US), Advanced Analytical Solutions (US), American
Industrial Hygiene Association (US), Matrix Sciences (US), Aashvi Proficiency
Testing & Analytical Services (India), and Global Proficiency (New
Zealand).
LGC Limited (UK) is the leading player in the laboratory
proficiency testing market. The company provides a wide range of proficiency
testing solutions under its flagship brand–AXIO. The company provides
proficiency testing schemes with support across a global network to 13,000
laboratories in more than 160 countries, which conducts approximately 2,000
proficiency tests every year. The company is mainly focusing on organic
strategies such as product launches to maintain and improve its share in the
market. For instance, in April 2020, the company launched a proficiency testing
(PT) service for the detection of SARS-CoV-2 (COVID 19) by nucleic acid
amplification testing. Also, in January 2018, the company launched human
blood-sirolimus (ERM-DA111a), an immunosuppressant certified reference
material, and Triiodothyronine Kit, calibration verification kit. LGC Limited
also pursues the strategy of expansions. In this regard, in June 2021, the
company announced the development of a new business group to provide supply
chain assurance solutions for the manufacturing, laboratory, ingredients, and
nutritional supplements sectors.
College of American
Pathologists held
the second position in the laboratory proficiency testing market. In 2020, more
than 25,000 laboratories enrolled in proficiency testing (PT) programs and the
CAP accredited more than 5,000 laboratories worldwide. Over 25,000 laboratories
are using CAP proficiency testing programs across the globe. The company has a
strong focus on enhancing its PT service portfolio in the proficiency testing
market through both organic and inorganic growth strategies, such as product
launches and investments. For instance, in April 2020, the company launched a
new proficiency testing (PT) program for the detection of severe acute respiratory
syndrome coronavirus 2 (SARS CoV-2). The company also continued to fund
programs that meet the members’ top needs. In 2020, the company invested USD
10.2 million into high-quality, practical learning and member conferences.
Throughout the COVID-19 pandemic, the company has been working to help navigate
the unique complexity and compliance requirements of SARS-CoV-2 testing along
with everyday high-quality laboratory management and testing for patients.
Request Sample Pages:-https://www.marketsandmarkets.com/requestsampleNew.asp?id=144227949
Bio-Rad Laboratories is one of the leading players in the
laboratory proficiency testing market. The company supplies more than 3,000
products covering more than 300 clinical diagnostic tests. It has a wide range
of product offerings for the Life Science and Clinical Diagnostics segments.
The Clinical Diagnostics segment observed a decrease of 7.6% in revenue in 2020
as compared to 2019. Although there were a few fluctuations in demand, the
overall sales were largely unaffected. With its strong geographic presence and
wide distribution network, Bio-Rad Laboratories has established itself as a
leader in the global market. The company offers fully accredited PT/EQA
programs in chemistry (serum and urine), immunoassay, therapeutic drugs, and
hematology. The EQAS program is fully accredited with ISO/IEC 17043:2010.